C-390 as sole selective agent for isolation of psedomonas aeruginosa from hospital waste water / by 274068 Havelaar, A. H., During, M.

A clinical-grade gene therapy vector for pharmacoresistant epilepsy successfully overexpresses NPY in a human neuronal cell line by Patrício, M, Barnard, A, Green, A, During, M, Sen, A, MacLaren, R

Eukaryotic and prokaryotic stomatins: the proteolytic link. by Green, J, Fricke, B, Chetty, M, von Düring, M, Preston, G, Stewart, G

AAV2/2-CBA-REP1 Vector with WPRE Provides Functional Expression of the Transgene in Choroideremia Mouse Knock-Out and Patient Cells by Tolmachova, T, Tolmachov, O, Barnard, A, Groppe, M, During, M, MacLaren, R, Seabra, M

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)... by Nauck, M, Frid, A, Hermansen, K, Shah, N, Tankova, T, Mitha, I, Zdravkovic, M, Düring, M, Matthews, DR

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study by Nauck, M, Frid, A, Hermansen, K, Thomsen, AB, During, M, Shah, N, Tankova, T, Mitha, I, Matthews, D

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes by Nauck, M, Frid, A, Hermansen, K, Shah, N, Tankova, T, Mitha, I, Zdravkovic, M, Düring, M, Matthews, DR

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. by Nauck, M, Frid, A, Hermansen, K, Thomsen, AB, During, M, Shah, N, Tankova, T, Mitha, I, Matthews, DR

Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin by Hermansen, K, Nauck, M, Frid, A, Shah, N, Tankova, T, Mitha, I, During, M, Zdravkovic, M, Matthews, D

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a... by Jendle, J, Nauck, M, Matthews, DR, Frid, A, Hermansen, K, Düring, M, Zdravkovic, M, Strauss, B, Garber, A

The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visce... by Jendle, J, Nauck, M, Matthews, D, Frid, A, Hermansen, K, During, M, Zdravkovic, M, Strauss, B, Garber, A

Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina by Charbel Issa, P, Silva, D, Lipinski, D, Singh, MS, Mouravlev, A, You, Q, Barnard, A, Hankins, M, During, M, Maclaren, R

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. by Maclaren, R, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Seymour, L, Clark, K, During, M, Cremers, F, Black, G, Lotery, A, Downes, S, Webster, A, Seabra, M

Retinal gene therapy in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial by MacLaren, R, MacLaren, R, MacLaren, R, Groppe, M, Groppe, M, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Seymour, L, Reed Clark, K, During, M, Cremers, F, Black, G, Lotery, A, Downes, S, Downes, S, Webster, A, Webster, A, Seabra, M, Seabra, M